Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease